# Incretin Microdosing for Cardiometabolic Health in People With HIV

> **NCT07325500** · PHASE2 · RECRUITING · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 30 (estimated)

## Conditions studied

- Weight Gain

## Interventions

- **DRUG:** Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly
- **DRUG:** Dose escalation to 2 mg semaglutide weekly then no semaglutide

## Key facts

- **NCT ID:** NCT07325500
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2028-05-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07325500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07325500, "Incretin Microdosing for Cardiometabolic Health in People With HIV". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07325500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*